Ambulantes psychosoziales Screening in einem Hautkrebszentrum: Akzeptanz, psychosoziale Belastung und Inanspruchnahme von Beratungsangeboten : Eine Post-hoc-Analyse im Rahmen der Qualitätssicherung
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Deutsch
- Bibliographic citation
-
Ambulantes psychosoziales Screening in einem Hautkrebszentrum: Akzeptanz, psychosoziale Belastung und Inanspruchnahme von Beratungsangeboten ; day:8 ; month:5 ; year:2024 ; pages:1-9
Die Dermatologie ; (8.5.2024), 1-9
- Classification
-
Soziale Probleme, Sozialdienste, Versicherungen
- Keyword
-
Psychosoziale Beratung
Psychosoziale Belastung
Psychoonkologie
Patient
Krebs
Psychosoziale Versorgung
Deutschland
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00105-024-05347-2
- URN
-
urn:nbn:de:101:1-2407172134021.839825884495
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:04 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wünsch, Alexander
- Jeske, Niklas
- Röderer, Natalie
- Meiß, Frank
- SpringerLink (Online service)
Other Objects (12)
Untersuchungen zum Einfluß des arteriellen Leberblutflusses und von Sauerstoff auf die Leberfunktion bei Patienten mit Zirrhose
Ambulantes psychosoziales Screening in einem Hautkrebszentrum: Akzeptanz, psychosoziale Belastung und Inanspruchnahme von Beratungsangeboten : = Outpatient psychosocial screening in a skin cancer center: acceptance, psychosocial distress and utilization of support : a post hoc analysis in a quality management program
Real world outcomes using PD‐1 antibodies and BRAF+ MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
Treatment management forBRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
S2k‐Leitlinie – Kutane Lymphome (ICD10 C82–C86): Update 2021
S2k‐Guidelines – Cutaneous lymphomas (ICD10 C82 ‐ C86): update 2021
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma – an evaluation of the multicenter prospective skin cancer registry ADOREG
Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
Small-vessel vasculitis after ST-segment elevation myocardial infarction
Untersuchungen zum Einfluß des arteriellen Leberblutflusses und von Sauerstoff auf die Leberfunktion bei Patienten mit Zirrhose
Ambulantes psychosoziales Screening in einem Hautkrebszentrum: Akzeptanz, psychosoziale Belastung und Inanspruchnahme von Beratungsangeboten : = Outpatient psychosocial screening in a skin cancer center: acceptance, psychosocial distress and utilization of support : a post hoc analysis in a quality management program
Real world outcomes using PD‐1 antibodies and BRAF+ MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
Treatment management forBRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
S2k‐Leitlinie – Kutane Lymphome (ICD10 C82–C86): Update 2021
S2k‐Guidelines – Cutaneous lymphomas (ICD10 C82 ‐ C86): update 2021
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma – an evaluation of the multicenter prospective skin cancer registry ADOREG
Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
Small-vessel vasculitis after ST-segment elevation myocardial infarction
Untersuchungen zum Einfluß des arteriellen Leberblutflusses und von Sauerstoff auf die Leberfunktion bei Patienten mit Zirrhose
Ambulantes psychosoziales Screening in einem Hautkrebszentrum: Akzeptanz, psychosoziale Belastung und Inanspruchnahme von Beratungsangeboten : = Outpatient psychosocial screening in a skin cancer center: acceptance, psychosocial distress and utilization of support : a post hoc analysis in a quality management program
Real world outcomes using PD‐1 antibodies and BRAF+ MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
Treatment management forBRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
S2k‐Leitlinie – Kutane Lymphome (ICD10 C82–C86): Update 2021
S2k‐Guidelines – Cutaneous lymphomas (ICD10 C82 ‐ C86): update 2021
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma – an evaluation of the multicenter prospective skin cancer registry ADOREG
Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients